Jeffrey Meisner
Senior Director, Development Locus Biosciences
Seminars
Wednesday 1st April 2026
Pioneering Precision Microbiome Therapeutics to Achieve Sustained Remission in Ulcerative Colitis
9:30 am
- Highlight clinical evidence linking specific bacterial consortia to remission in ulcerative colitis and how these insights inform rational product design
- Discuss translational and clinical strategies for demonstrating efficacy, engraftment, and durability in LBP development
- Examine how precision patient profiling and microbial biomarkers can optimize trial design and therapeutic response
